Cargando…

Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes

Detalles Bibliográficos
Autores principales:	Galtier, Jean, Alric, Camille, Bérard, Emilie, Leguay, Thibaut, Tavitian, Suzanne, Bidet, Audrey, Delabesse, Eric, Rieu, Jean Baptiste, Vial, Jean-Philippe, Vergez, François, Lechevalier, Nicolas, Luquet, Isabelle, Klein, Emilie, de Grande, Anne-Charlotte, Sarry, Audrey, Pigneux, Arnaud, Récher, Christian, Bertoli, Sarah, Dumas, Pierre-Yves
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590686/ https://www.ncbi.nlm.nih.gov/pubmed/34775463 http://dx.doi.org/10.1038/s41408-021-00551-y

Ejemplares similares

Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study
por: Bertoli, Sarah, et al.
Publicado: (2020)

Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study
por: Dumas, Pierre-Yves, et al.
Publicado: (2020)

Vitamin C and D supplementation in acute myeloid leukemia
por: Mouchel, Pierre Luc, et al.
Publicado: (2023)

Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia
por: Vergez, François, et al.
Publicado: (2022)

CD34(+)CD38(−)CD123(+) Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents
por: Vergez, François, et al.
Publicado: (2020)

Genomic landscape of hyperleukocytic acute myeloid leukemia
por: Largeaud, Laetitia, et al.
Publicado: (2022)

Outcome of patients aged 60‐75 years with newly diagnosed secondary acute myeloid leukemia: A single‐institution experience
por: Bertoli, Sarah, et al.
Publicado: (2019)

Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia
por: Vial, Jean Philippe, et al.
Publicado: (2021)

Improved outcome for AML patients over the years 2000–2014
por: Bertoli, Sarah, et al.
Publicado: (2017)

Retrospective Comparison of Fludarabine in Combination With Intermediate-Dose Cytarabine Versus High-Dose Cytarabine As Consolidation Therapies for Acute Myeloid Leukemia
por: Zhang, Wenjun, et al.
Publicado: (2014)

Dexamethasone in hyperleukocytic acute myeloid leukemia
por: Bertoli, Sarah, et al.
Publicado: (2018)

Hand foot syndrome associated with standard dose cytarabine
por: Sharma, Atul, et al.
Publicado: (2013)

Exploiting the DNA Damaging Activity of Liposomal Low Dose Cytarabine for Cancer Immunotherapy
por: Lewicky, Jordan D., et al.
Publicado: (2022)

Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia
por: Dumas, Pierre-Yves, et al.
Publicado: (2017)

Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo
por: Serhan, Nizar, et al.
Publicado: (2020)

Intermediate dose cytarabine improves survival and relapse-free rate compared with standard-dose cytarabine as post-remission treatment for acute myeloid leukemia: A retrospection study
por: Ye, Li, et al.
Publicado: (2021)

Cerebral localization of chronic myelomonocytic leukemia and improvement with high‐dose cytarabine: A case report
por: Haméon, Clémence, et al.
Publicado: (2023)

Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experience
por: Bashir, Yasir, et al.
Publicado: (2015)

Intermediate-dose cytarabine is an effective therapy for adults with non-Langerhans cell histiocytosis
por: Liu, Ting, et al.
Publicado: (2022)

Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies
por: Bertoli, Sarah, et al.
Publicado: (2016)

Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy
por: Laloi, Louise, et al.
Publicado: (2022)

Cost comparison of post-remission strategies in younger and older AML patients in France
por: Mounie, Michael, et al.
Publicado: (2023)

Safety and Feasibility of Outpatient High Dose Cytarabine for Acute Myeloid Leukemia in the Brazilian Amazon
por: Rodrigues, Amanda Lopes Maia, et al.
Publicado: (2020)

Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia
por: Canaani, Jonathan, et al.
Publicado: (2020)

Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers
por: Di Francia, Raffaele, et al.
Publicado: (2021)

Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia
por: Wei, Hui, et al.
Publicado: (2020)

A clinical report on high‑dose cytarabine therapy for children with acute myeloid leukemia
por: Wu, Ziliang, et al.
Publicado: (2022)

Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia
por: Anders, Brandi, et al.
Publicado: (2017)

Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia
por: Patzke, Ciera L., et al.
Publicado: (2020)

High-Dose Cytarabine in Acute Myeloid Leukemia Treatment: A Systematic Review and Meta-Analysis
por: Li, Wei, et al.
Publicado: (2014)

Treatment of acute erythroleukaemia with high‐dose cytarabine in a cat with feline leukaemia virus infection
por: Park, Da Sol, et al.
Publicado: (2021)

Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2022)

Early-stage corneal toxicity secondary to high-dose systemic cytarabine: a case report
por: Mito, Tsuyoshi, et al.
Publicado: (2023)

Cytarabine-Induced Encephalitis
por: Lenfant, Christine, et al.
Publicado: (2021)

High-dose cytarabine monotherapy is superior to standard-dose cytarabine- based multiagent sequential treatment cycle for consolidation treatment in adult (14-59 years) AML patients according to European Leukemia Net 2022 risk stratification
por: Wang, Xiaoyu, et al.
Publicado: (2023)

A quality‐adjusted survival time without symptoms or toxicities analysis of glasdegib plus low‐dose cytarabine versus low‐dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy
por: Solem, Caitlyn T., et al.
Publicado: (2020)

A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML
por: Schwarer, Anthony P., et al.
Publicado: (2018)

Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
por: Ferrara, Felicetto
Publicado: (2020)

PB1838: TOXICITY AND OUTCOME OF HIGH DOSE CYTARABINE (18 G/M2) FOR AML CONSOLIDATION.
por: Lopes, L., et al.
Publicado: (2022)

Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia
por: Smoljo, Tomislav, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_26mf24q0a0cnc5rb69djkmt2ri